The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch

    157 Aufrufe 157 0 Kommentare 0 Kommentare
    The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch

    Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability

    Highlights

    • Order placed for 20,000 units of the Company's needle-free Thymosin Alpha-1 transdermal patch in preparation for commercial release
    • TA1 is a naturally occurring peptide studied for its immune-modulating properties, historically delivered by injection¹
    • The Company believes it could be among the first to market with a Thymosin Alpha-1 transdermal patch.
    • Second product to move from the Company's transdermal development pipeline into commercial production
    • Each patch is formulated to deliver 2 mg of TA1, consistent with the results reported in the Company's September 8, 2026 news release
    • 100% manufactured and tested in the United States

    Vancouver, British Columbia--(Newsfile Corp. - October 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its Thymosin Alpha-1 ("TA1") transdermal patch (the "Patch"). The order is intended to support the Patch's planned commercial release and represents the Company's initial commercial production run of the product. Each Patch is formulated to deliver 2 mg of TA1.

    The order follows the Company's September 8, 2026 news release, "The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing," regarding the development of its Thymosin Alpha-1 transdermal patch. The order is for patches formulated with a 2 mg dose of Thymosin Alpha-1.

    TA1 is a naturally occurring peptide present in the thymus that has been studied for its immune-modulating properties.¹ In the clinical studies included in a 2025 systematic review and meta-analysis, TA1 was administered by subcutaneous injection.¹ That study did not evaluate the Company's patch, which remains under development and testing. The Patch is designed as a wearable wellness product that applies directly to the skin, with no injections, no reconstitution and no user-administered dose measurement.

    The Patch is the second product to advance through the Company's transdermal development pathway into commercial production, following the BPC-157 patch. Based on its review of currently available products, the Company believes it could be among the first to market with a TA1 transdermal patch.

    Seite 1 von 3 






    Verfasst von newsfile
    The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availabilityHighlightsOrder placed for 20,000 units of the Company's needle-free Thymosin Alpha-1 …

    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Profitieren Sie von unserem Alleinstellungsmerkmal als den zentralen verlagsunabhängigen Wissens-Hub für einen aktuellen und fundierten Zugang in die Börsen- und Wirtschaftswelt, um strategische Entscheidungen zu treffen.
    • ✅ Größte Finanz-Community Deutschlands
    • ✅ über 550.000 registrierte Nutzer
    • ✅ rund 2.000 Beiträge pro Tag
    • ✅ verlagsunabhängige Partner ARIVA, FinanzNachrichten und BörsenNews
    • ✅ Jederzeit einfach handeln beim SMARTBROKER+
    • ✅ mehr als 25 Jahre Marktpräsenz
    Aktien von A - Z: # A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    wallstreetONLINE bei X wallstreetONLINE bei Instagram wallstreetONLINE bei Facebook wallstreetONLINE bei Youtube wallstreetONLINE bei LinkedIn
    Unsere Apps: Apple App Store Icon Google Play Store Icon
    Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

    Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
    Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
    Copyright © 1998-2026 Smartbroker Holding AG - Alle Rechte vorbehalten.
    Mit Unterstützung von: Ariva Smartbroker+
    Daten & Kurse von: TTMzero